Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYActa naturae

A Novel Targeted Conjugate for Photodynamic Therapy of HER2-Positive Cancer.

  • I P Sharychev1
  • A A Prach1,2
  • E V Plotnikov1,3,4
  • M S Larkina1,3
  • P V Petunin1
  • M V Belousov1,3
  • E V Konovalova1,5
  • A A Shulga1,5
  • S M Deev1,5
5 affiliations
  1. 1National Research Tomsk Polytechnic University, Tomsk, 634050 Russia.
  2. 2Laboratory of Molecular Cancer Therapy, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, 634028 Russia.
  3. 3Siberian State Medical University, Tomsk, 634050 Russia.
  4. 4Mental Health Research Institute of the Tomsk National Research Medical Center, Tomsk, 634014 Russia.
  5. 5Molecular Immunology Laboratory, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.
Read full textPDFDOICite

Abstract

Low selectivity against cancer cells remains one of the key challenges of many modern photosensitizers. To enhance the selectivity of the action and the effectiveness of tumor therapy, a conjugate was developed comprising a photoactive compound, the water-soluble silicon phthalocyanine complex (IR700, IRDye 700DX NHS ester), and the targeted molecule DARPin G3-ABD, which is designed to target human epidermal growth factor receptor type 2 (HER2). The phototoxicity of the individual substance IR700 and the DARPin G3-ABD-IR700 conjugate was tried on tumor cell cultures with different HER2 expression levels (SKBR-3, SKOV-3, BT-474, and PC-3). The cells were irradiated using LED diodes with a wavelength of 690 nm and a luminous flux density of 0.5 W/cm². Cell viability after irradiation and following all the experimental procedures was evaluated using the standard MTT assay. The developed conjugate proved to specifically bind to HER2 receptors. The combination of high photosensitizing activity and selectivity of action against tumor cells makes the DARPin G3-ABD-IR700 conjugate a promising targeted agent for photodynamic therapy.

Related

  1. Smart Theranostic Nanoplatforms in Oral Squamous Cell Carcinoma: Integrating Diagnosis, Targeted Therapy and Synergistic Photothermal/Photodynamic Approaches
    Ludovica Lucchesi Palli, Cinzia Scialabba, Gennara Cavallaro
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General biochemistryCrossref
  2. A novel peptide–drug conjugate GV-K for anti-colorectal cancer therapy via mitochondrial apoptosis
    Lifeng Yu, Ying He, Guojia Liu +12
    Acta pharmaceutica Sinica. BPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMCPMC
  3. Modeling a continuum of drug-induced persistence during targeted cancer therapy
    Ji Tae Park, Herbert Levine
    Proceedings of the National Academy of Sciences of the United States of AmericaPeer-reviewedCC BY-NC-ND 4.0Full text3 citedMolecular biology & gene regulationPMC
  4. Mitochondria-targeted DZ-1-dihydroartemisinin conjugate induces Bax/Bak-independent apoptotic cell death in colorectal carcinoma cells
    Farzaneh Vafaeinik, Yi Zhang, Heuiran Lee +6
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textMolecular biology & gene regulationCrossref
  5. Chirality and morphology-dependent siRNA delivery for targeted lung cancer therapy with intrinsically chiral gold nanoparticles.
    Qiusha Li, Jinglei Xu, En Zhang +5
    Materials today. BioPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC

Cite

BibTeXRIS
BibTeX
@article{sharychev2026novel,
  title = {{A Novel Targeted Conjugate for Photodynamic Therapy of HER2-Positive Cancer.}},
  author = {I P Sharychev and A A Prach and E V Plotnikov and M S Larkina and P V Petunin and M V Belousov and E V Konovalova and A A Shulga and S M Deev},
  journal = {Acta naturae},
  year = {2026},
  month = jul,
  doi = {10.32607/actanaturae.27891},
  url = {https://europepmc.org/article/MED/42960098},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - A Novel Targeted Conjugate for Photodynamic Therapy of HER2-Positive Cancer.
AU  - I P Sharychev
AU  - A A Prach
AU  - E V Plotnikov
AU  - M S Larkina
AU  - P V Petunin
AU  - M V Belousov
AU  - E V Konovalova
AU  - A A Shulga
AU  - S M Deev
PY  - 2026
DA  - 2026/07/01
JO  - Acta naturae
DO  - 10.32607/actanaturae.27891
UR  - https://europepmc.org/article/MED/42960098
AB  - Low selectivity against cancer cells remains one of the key challenges of many modern photosensitizers. To enhance the selectivity of the action and the effectiveness of tumor therapy, a conjugate was developed comprising a photoactive compound, the water-soluble silicon phthalocyanine complex (IR700, IRDye 700DX NHS ester), and the targeted molecule DARPin G3-ABD, which is designed to target human epidermal growth factor receptor type 2 (HER2). The phototoxicity of the individual substance IR700 and the DARPin G3-ABD-IR700 conjugate was tried on tumor cell cultures with different HER2 expression levels (SKBR-3, SKOV-3, BT-474, and PC-3). The cells were irradiated using LED diodes with a wavelength of 690 nm and a luminous flux density of 0.5 W/cm². Cell viability after irradiation and following all the experimental procedures was evaluated using the standard MTT assay. The developed conjugate proved to specifically bind to HER2 receptors. The combination of high photosensitizing activity and selectivity of action against tumor cells makes the DARPin G3-ABD-IR700 conjugate a promising targeted agent for photodynamic therapy.
SN  - 2075-8251
ER  -